Skip to main content
SK Bioscience Co.,Ltd logo

SK Bioscience Co.,Ltd — Investor Relations & Filings

Ticker · 302440 ISIN · KR7302440003 KO Manufacturing
Open in API
Filings indexed 381 across all filing types
Latest filing 2024-09-25 Capital/Financing Update
Country KR South Korea
Listing KO 302440

About SK Bioscience Co.,Ltd

https://www.skbioscience.com/

SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.

Recent filings

Filing Released Lang Actions
[기재정정]타인에대한채무보증결정
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding a 'Decision on Debt Guarantee for Others' (타인에 대한 채무보증결정). It is a formal disclosure of a financial guarantee provided by the company for its subsidiary, including specific financial figures, dates, and board resolution details. As it does not fit into specific categories like M&A, Dividends, or Earnings, and is a standard regulatory disclosure filed with the KRX (Korea Exchange), it is classified as a Regulatory Filing.
2024-09-25 Korean
타인에대한채무보증결정
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from SK Bioscience regarding a 'Decision on Debt Guarantee for Others' (타인에 대한 채무보증 결정). It details the financial guarantee provided by the company for its subsidiary's acquisition target (IDT Biologika GmbH), including the amount, duration, and board approval details. As this is a specific regulatory disclosure regarding corporate financial obligations that does not fit into categories like M&A (which would be the acquisition itself) or capital changes, it falls under the general regulatory filing category.
2024-09-11 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) for SK Bioscience. It details the correction of specific terms such as payment dates, listing dates, and dividend calculation dates for a third-party capital increase. This is a regulatory filing concerning capital structure changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2024-09-11 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Regulatory Filings Classification · 1% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by SK Bioscience. It provides specific regulatory data regarding group affiliation, internal transactions, and guarantees as required by Korean fair trade regulations. Since it is a mandatory regulatory disclosure of corporate status and group-level financial/operational data that does not fit into standard financial reporting categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2024-08-30 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for SK Bioscience, covering the period from 2024.01.01 to 2024.06.30. It contains detailed financial information, business operations, management discussions, and organizational structure, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-13 Korean
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Environmental & Social Information Classification · 1% confidence The document is a regulatory disclosure regarding payment methods, payment periods, and dispute resolution mechanisms under the Fair Transactions in Subcontracting Act (Article 13-3). It is a specific compliance filing required by Korean regulatory authorities for companies to report their subcontracting payment practices. Since it does not fit into financial reporting, governance, or shareholder-specific categories, it is best classified as a general regulatory filing.
2024-08-12 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.